Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01878708 · ClinicalTrials.gov registry record · Early Phase 1
A Pilot Study of Oncaspar® + Dexamethasone in Patients With Relapsed or Refractory T-Cell Lymphoma
A Early Phase 1 study, sponsored by Dana-Farber Cancer Institute.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 2
- Enrollment target
NCT01878708: Clinical Trial Early Phase 1 study, sponsored by Dana-Farber Cancer Institute.
NCT01878708 is a Early Phase 1 study that was terminated before completion, run by Dana-Farber Cancer Institute. The registered enrollment target is 2 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01878708, a Early Phase 1 study, was terminated before completion, sponsored by Dana-Farber Cancer Institute.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
This is an open-label, single-arm pilot study of Oncaspar® with dexamethasone for patients with relapsed or refractory peripheral T-cell lymphoma (PTCL), excluding extranodal NK/T cell lymphoma (ENKTL). Patients will receive up to 8 courses of treatment.
Interventions
- DRUG Dexamethasone acetate
- DRUG PEG-L-asparaginase
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2013-07 |
| Est. Completion | 2017-02 |
| Phase | Early Phase 1 |
Why NCT01878708 stopped before completion
NCT01878708 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 2 interventions - of which Dexamethasone acetate is the first listed.
NCT01878708 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01878708 about?
NCT01878708 is a clinical study titled "A Pilot Study of Oncaspar® + Dexamethasone in Patients With Relapsed or Refractory T-Cell Lymphoma". This is an open-label, single-arm pilot study of Oncaspar® with dexamethasone for patients with relapsed or refractory peripheral T-cell lymphoma (PTCL), excluding extranodal NK/T cell lymphoma (ENKTL). Patients will receive up to 8 courses of treatment.
What is the current status of trial NCT01878708?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 2 participants. The study started on 2013-07. Estimated completion is 2017-02.
What interventions are being tested in trial NCT01878708?
The interventions under investigation include: Dexamethasone acetate (DRUG), PEG-L-asparaginase (DRUG).
Who is sponsoring clinical trial NCT01878708?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01878708's enrollment target sits among peer trials
2 1973rd of 2000 higher than 16 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia